BCL2L1 and B-cell chronic lymphocytic leukemia: Moreover, these inhibitors may also directly target the microenvironment: in CLL patients, T-cell activation and proliferation is strongly reduced after inhibition of the BCR signalosome, thereby preventing T-cell-mediated upregulation of MCL-1 and BCL-XL in CLL cells and subsequent venetoclax resistance [52].